Heterogeneous effect of peroxisome proliferator-activated receptor γ2 Ala12 variant on Type 2 diabetes risk

Ornella Ludovico, Fabio Pellegrini, Rosa Di Paola, Antonio Minenna, Sandra Mastroianno, Marina Cardellini, Maria Adelaide Marini, Francesco Andreozzi, Olga Vaccaro, Giorgio Sesti, Vincenzo Trischitta

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Conflicting results have been reported regarding whether the PPARγ2 Pro12Ala polymorphism plays a role in the risk of type 2 diabetes (T2D), suggesting genetic heterogeneity. To investigate this issue, a meta-analysis of 41 published and 2 unpublished studies (a total of 42,910 subjects) was conducted. Ala12 carriers had a 19% T2D risk reduction, but this association was highly heterogeneous (p = 0.005). A great proportion (48%) of heterogeneity was explained by the controls' BMI, with risk reduction being greater when BMI was lower. Risk reduction of Ala12 carriers in Asia (35%) was higher than in Europe (15%, p = 0.02) and tended to be higher than in North America (18%, p = 0.10). Difference between Asians and Europeans was no longer significant (p = 0.15) after adjusting for the controls' BMI. Studies from Europe were still heterogeneous (p = 0.02) with risk reduction in Ala12 carriers being progressively smaller (test for trend in the odds ratios, p = 0.02) from Northern (26% reduction,p <0.0001) to Central (10%, p = 0.04) and Southern (0%, p = 0.94) Europe. In conclusion, in our meta-analysis, the reduced risk of T2D in Ala12 carriers is not homogeneous. It is greater in Asia than in Europe and, among Europeans, it is higher in Northern Europe, barely significant in Central Europe, and nonexistent in Southern Europe.

Original languageEnglish
Pages (from-to)1076-1081
Number of pages6
JournalObesity
Volume15
Issue number5
DOIs
Publication statusPublished - May 2007

Fingerprint

Peroxisome Proliferator-Activated Receptors
Type 2 Diabetes Mellitus
Risk Reduction Behavior
Meta-Analysis
Genetic Heterogeneity
North America
Odds Ratio

Keywords

  • Candidate genes
  • Genetic susceptibility
  • Peroxisome proliferator-activated receptor
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology
  • Medicine (miscellaneous)
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics

Cite this

Heterogeneous effect of peroxisome proliferator-activated receptor γ2 Ala12 variant on Type 2 diabetes risk. / Ludovico, Ornella; Pellegrini, Fabio; Di Paola, Rosa; Minenna, Antonio; Mastroianno, Sandra; Cardellini, Marina; Marini, Maria Adelaide; Andreozzi, Francesco; Vaccaro, Olga; Sesti, Giorgio; Trischitta, Vincenzo.

In: Obesity, Vol. 15, No. 5, 05.2007, p. 1076-1081.

Research output: Contribution to journalArticle

Ludovico, O, Pellegrini, F, Di Paola, R, Minenna, A, Mastroianno, S, Cardellini, M, Marini, MA, Andreozzi, F, Vaccaro, O, Sesti, G & Trischitta, V 2007, 'Heterogeneous effect of peroxisome proliferator-activated receptor γ2 Ala12 variant on Type 2 diabetes risk', Obesity, vol. 15, no. 5, pp. 1076-1081. https://doi.org/10.1038/oby.2007.617
Ludovico, Ornella ; Pellegrini, Fabio ; Di Paola, Rosa ; Minenna, Antonio ; Mastroianno, Sandra ; Cardellini, Marina ; Marini, Maria Adelaide ; Andreozzi, Francesco ; Vaccaro, Olga ; Sesti, Giorgio ; Trischitta, Vincenzo. / Heterogeneous effect of peroxisome proliferator-activated receptor γ2 Ala12 variant on Type 2 diabetes risk. In: Obesity. 2007 ; Vol. 15, No. 5. pp. 1076-1081.
@article{8765a0a517bf4a77a5c90442a3459969,
title = "Heterogeneous effect of peroxisome proliferator-activated receptor γ2 Ala12 variant on Type 2 diabetes risk",
abstract = "Conflicting results have been reported regarding whether the PPARγ2 Pro12Ala polymorphism plays a role in the risk of type 2 diabetes (T2D), suggesting genetic heterogeneity. To investigate this issue, a meta-analysis of 41 published and 2 unpublished studies (a total of 42,910 subjects) was conducted. Ala12 carriers had a 19{\%} T2D risk reduction, but this association was highly heterogeneous (p = 0.005). A great proportion (48{\%}) of heterogeneity was explained by the controls' BMI, with risk reduction being greater when BMI was lower. Risk reduction of Ala12 carriers in Asia (35{\%}) was higher than in Europe (15{\%}, p = 0.02) and tended to be higher than in North America (18{\%}, p = 0.10). Difference between Asians and Europeans was no longer significant (p = 0.15) after adjusting for the controls' BMI. Studies from Europe were still heterogeneous (p = 0.02) with risk reduction in Ala12 carriers being progressively smaller (test for trend in the odds ratios, p = 0.02) from Northern (26{\%} reduction,p <0.0001) to Central (10{\%}, p = 0.04) and Southern (0{\%}, p = 0.94) Europe. In conclusion, in our meta-analysis, the reduced risk of T2D in Ala12 carriers is not homogeneous. It is greater in Asia than in Europe and, among Europeans, it is higher in Northern Europe, barely significant in Central Europe, and nonexistent in Southern Europe.",
keywords = "Candidate genes, Genetic susceptibility, Peroxisome proliferator-activated receptor, Type 2 diabetes",
author = "Ornella Ludovico and Fabio Pellegrini and {Di Paola}, Rosa and Antonio Minenna and Sandra Mastroianno and Marina Cardellini and Marini, {Maria Adelaide} and Francesco Andreozzi and Olga Vaccaro and Giorgio Sesti and Vincenzo Trischitta",
year = "2007",
month = "5",
doi = "10.1038/oby.2007.617",
language = "English",
volume = "15",
pages = "1076--1081",
journal = "Obesity",
issn = "1930-7381",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Heterogeneous effect of peroxisome proliferator-activated receptor γ2 Ala12 variant on Type 2 diabetes risk

AU - Ludovico, Ornella

AU - Pellegrini, Fabio

AU - Di Paola, Rosa

AU - Minenna, Antonio

AU - Mastroianno, Sandra

AU - Cardellini, Marina

AU - Marini, Maria Adelaide

AU - Andreozzi, Francesco

AU - Vaccaro, Olga

AU - Sesti, Giorgio

AU - Trischitta, Vincenzo

PY - 2007/5

Y1 - 2007/5

N2 - Conflicting results have been reported regarding whether the PPARγ2 Pro12Ala polymorphism plays a role in the risk of type 2 diabetes (T2D), suggesting genetic heterogeneity. To investigate this issue, a meta-analysis of 41 published and 2 unpublished studies (a total of 42,910 subjects) was conducted. Ala12 carriers had a 19% T2D risk reduction, but this association was highly heterogeneous (p = 0.005). A great proportion (48%) of heterogeneity was explained by the controls' BMI, with risk reduction being greater when BMI was lower. Risk reduction of Ala12 carriers in Asia (35%) was higher than in Europe (15%, p = 0.02) and tended to be higher than in North America (18%, p = 0.10). Difference between Asians and Europeans was no longer significant (p = 0.15) after adjusting for the controls' BMI. Studies from Europe were still heterogeneous (p = 0.02) with risk reduction in Ala12 carriers being progressively smaller (test for trend in the odds ratios, p = 0.02) from Northern (26% reduction,p <0.0001) to Central (10%, p = 0.04) and Southern (0%, p = 0.94) Europe. In conclusion, in our meta-analysis, the reduced risk of T2D in Ala12 carriers is not homogeneous. It is greater in Asia than in Europe and, among Europeans, it is higher in Northern Europe, barely significant in Central Europe, and nonexistent in Southern Europe.

AB - Conflicting results have been reported regarding whether the PPARγ2 Pro12Ala polymorphism plays a role in the risk of type 2 diabetes (T2D), suggesting genetic heterogeneity. To investigate this issue, a meta-analysis of 41 published and 2 unpublished studies (a total of 42,910 subjects) was conducted. Ala12 carriers had a 19% T2D risk reduction, but this association was highly heterogeneous (p = 0.005). A great proportion (48%) of heterogeneity was explained by the controls' BMI, with risk reduction being greater when BMI was lower. Risk reduction of Ala12 carriers in Asia (35%) was higher than in Europe (15%, p = 0.02) and tended to be higher than in North America (18%, p = 0.10). Difference between Asians and Europeans was no longer significant (p = 0.15) after adjusting for the controls' BMI. Studies from Europe were still heterogeneous (p = 0.02) with risk reduction in Ala12 carriers being progressively smaller (test for trend in the odds ratios, p = 0.02) from Northern (26% reduction,p <0.0001) to Central (10%, p = 0.04) and Southern (0%, p = 0.94) Europe. In conclusion, in our meta-analysis, the reduced risk of T2D in Ala12 carriers is not homogeneous. It is greater in Asia than in Europe and, among Europeans, it is higher in Northern Europe, barely significant in Central Europe, and nonexistent in Southern Europe.

KW - Candidate genes

KW - Genetic susceptibility

KW - Peroxisome proliferator-activated receptor

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=34250631631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250631631&partnerID=8YFLogxK

U2 - 10.1038/oby.2007.617

DO - 10.1038/oby.2007.617

M3 - Article

C2 - 17495182

AN - SCOPUS:34250631631

VL - 15

SP - 1076

EP - 1081

JO - Obesity

JF - Obesity

SN - 1930-7381

IS - 5

ER -